Creating new hope and better patient insights through precision diagnostics and therapeutics

Our Technology

Our unique antibody discovery platform for fully human antibodies, together with advanced antibody engineering capabilities, provides a pipeline for highly specific antibodies for use in therapeutics and diagnostics.

About Us


About Us

GEN-Y Biologics was formed in 2020 to license, productise and take to market superior antibody technologies derived from state-of-the-art technological platforms developed through their exclusive licensing partnership with National University of Singapores’s highly prestigious Life Sciences Institute

What We Do

Our technology employs a powerful method to screen human memory B cells from convalescent patients. Using a blend of bioinformatics, massive parallel sequencing and high throughput functional assays, we identify fully human monoclonal antibodies for research, therapy or diagnostics.

Delivering new solutions that improve outcomes for patients.



GEN-Y Biologics has an exciting pipeline of other development opportunities beyond the SARS-CoV-2 and Dengue assets. However, the initial focus for investment is on the Dengue portfolio – a portfolio that has the potential to represent a new paradigm in care of this infectious tropical disease.

Importantly, investors will benefit from the reassurance that GEN-Y Biologics is generating revenue from on-going ImTracker MULTI sales and from the early introduction of the Dengue Point of Care diagnostic arriving late 2022/early 2023.

Latest News

A fast, sensitive and specific Multiplex ELISA test for SARS-CoV-2 Neutralization

The ImTracker MULTI COVID-19 Viral Variant Neutralization Test is a serological enzyme-linked immunosorbent assay (ELISA) intended for the quantitative detection of neutralizing antibodies that block binding of the host receptor angiotensin converting enzyme-2 (ACE-2) to the receptor binding domain (RBD) of SARS-CoV-2.